Sending time2020-12-27 23:15
comment
Immune effects were different depending on the dose of the vaccine, but they showed confidence.
U.S. health authorities are examining whether to approve emergency use… Expected conclusions in the near future
[로이터=연합뉴스 자료사진]
(Paris = Yonhap News) Correspondent Hye-ran Hyun = The CEO of AstraZeneca, a multinational pharmaceutical company headquartered in London, UK, said on the 27th (local time) the success of a novel coronavirus infection (Corona 19) vaccine developed with Oxford University. I made myself.
Pascal Sorio (61), CEO of the Daily The Times, told The Times’ Sunday Times that, like other competitors, “I think we’ve figured out a formula for success that can benefit from two doses of vaccine.”
In an interview conducted by burns while staying at his home in Sydney, Australia, he said that “100% of the infection can be prevented” and “it can’t be said in detail because it will release a vaccine at some point.”
The COVID-19 vaccine developed by AstraZeneca and Oxford University showed different immunity effects depending on the dose as a result of interim analysis of the phase 3 clinical trial.
When the full dose of the vaccine was administered twice, the prevention rate was only 62.1%, but when the first half dose was administered and the second full dose, the prevention rate rose to 90.0%.
The average prevention rate is 70.4%, which is less effective than vaccines from Pfizer and German Bioentech (95%) and vaccines developed by US pharmaceutical company Modena (94.5%).
CEO Sorio admitted that he was “surprised” when he first discovered that the immune effects were different depending on the dose of the vaccine.
“Of course, I wish the results were simpler, but because they met the standards set by regulatory authorities around the world, I evaluated them positively,” he added. “I didn’t expect a storm to come.”
When AstraZeneca and Oxford University announced their interim clinical results last month, criticism was blamed for the difference in efficacy depending on the dosage and the stock price fell 3.8%.
CEO Sorio said AstraZeneca and Oxford University are currently working on a new version of the vaccine. I hope it is not necessary, but it is because preparations such as the variant corona 19 virus that appeared in South Africa are necessary.
On the 21st, AstraZeneca and Oxford University applied for emergency use of the Corona 19 vaccine made by both companies to the UK Medicines and Health Care Products Regulatory Authority (MHRA).
MHRA, which conducts non-stop deliberations even during the Christmas holidays, can announce whether the vaccine is approved for emergency use as early as the 27th, the Daily Telegraph reported.
Compared to other vaccines, the AstraZeneca-Oxford vaccine is inexpensive and can be stored in a general refrigerator, so the transport process is not difficult.
Unauthorized reproduction-prohibition of redistribution>
2020/12/27 23:15 sent